KIRhub 2.0· v2

Imatinib

33722b31-ca57-5da6-b6eb-c7c04a3f81c5 · FDA Approved · targets BCR_ABL, ABL1, ABL2_ARG

Imatinib

MeasuredReference

Imatinib targets PDGFRA, DDR1, CSF1R. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

PDGFRA DDR1 CSF1R LCK DDR2

Top hallmarks

tumor promoting inflammation2.6k
evading apoptosis2.1k
proliferation2.0k

Top pathways disrupted

apical junction5.1k
allograft rejection4.9k
pi3k akt mtor signaling4.4k

Resistance landscape — Imatinib

MeasuredReference

6 known oncogenic variants exist on Imatinib's top targets — see detail for inhibition impact.

PDGFRA 4 known variants
DDR2 2 known variants
- DDR2 (N456S)
- DDR2 (T654M)

Open in new tab